RxDoctor Payments Data

Oliver Reed, MD

Dermatology · Brooksville, FLNPI 1164461976

Payments from drug & device makers

$15,839in general payments, 2019–2025

Across 382 payments — averaging $41.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Johnson & Johnson$2K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Galderma Laboratories, L.p.$1K
  • UCB, Inc.$785
  • plus $6K from 34 others
$1,320in research payments, 2019–2025

Across 1 payment — averaging $1319.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K

What the payments were for

  • Consulting fees$1,3759%
  • Speaking & faculty fees$3502%
  • Food & beverage$13,53285%
  • Education$5824%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,839 in reported general payments places this provider in the 80th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida

Medicare billing

Part B allowed, 2024
$512,111
Medicare patients
1,240
Services billed
6,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast33$163,695
RinvoqUpadacitinib11$67,165
Dupixent PenDupilumab17$61,383
Clobetasol Propionate184$8,003
Ketoconazole339$5,610
Doxycycline Hyclate351$5,122
Triamcinolone Acetonide371$4,485
Acitretin14$3,327
Fluorouracil28$2,811
Mupirocin271$1,701
Metronidazole29$1,686
Imiquimod71$1,583
Hydrocortisone133$1,321
Spironolactone51$859
Clindamycin Phosphate35$682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$43$163,69533 claims
AbbVieRinvoq$1,570$67,16511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,147 dermatology providers in Florida.

Other dermatology in Brooksville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →